Acura Pharmaceuticals Inc. (ACUR)

mgbigsandco (< 20) Submitted: 11/2/2009 4:28:50 PM : Start Price: $4.10 ACUR Score: +3.89

When Acura gets approval for acurox it will put this small pharm co on the map. It also is developing tech for Impede Tech (tm) which will not allow pseuphede to be extracted to make meth. This as well as its tech to make pain meds less abusable is both HUGE!!! watch this one rise...at Q1 this will be up around 7 or 8 with approval it jumps to 13+ with poss buyout from King Pharm looming..get in on this one now!~

steelersnextat7 (< 20) Submitted: 9/22/2009 2:10:56 AM : Start Price: $4.88 ACUR Score: -10.32

FDA approval is looming in Jan to March 2010 when it does acura will hit 12 to 15 or be bought or both king will scoop it up

TSIF (98.76) Submitted: 6/29/2009 10:18:16 PM : Start Price: $6.01 ACUR Score: -48.40

Acura Pharmaceuticals got bloodied (36%) when it received word from the FDA that it had a "labeling" issue for it's experimental pain drug Acurox which would delay a response past the expected June 30th date. While this could be bad news, as it adds another layer to the process and delays, it appears to me to be as expected for a drug that includes oxycodone WHILE trying to meet the new FDA guidelines that attempt to curb prescription drug abuse, which can be common with opioid pain drugs. Acura's "Aversion(r)" (abuse deterrent) Technology, has the issue of being the first to test the new guidelines and it should not be unexpected for the FDA to ensure they are establishing a clear set of guidelines. Once through these hurdles Acura will be the "poster child" for the new rules and will be able to see it's drug where other companies cannot without similar approval. Several analysts expect the dreaded "complete response" letter from the FDA which could set things back 6-18 months if more data is needed, but this delay to me appears to only be a cautious approach from the FDA, not a formal "complete response". If I'm wrong, my CAPs will need some pain reliever!

TLassen (57.55) Submitted: 3/21/2009 1:24:34 PM : Start Price: $5.66 ACUR Score: -48.89

Ticker Symbol ACUR
Name of Company ACURA PHARMACEUTICAL
Date March 1, 2009
Earnings Report (Qtr/YR) 4TH QTR 2008

Strategic Score 71%

Intrinsic Value $5.21
Buy at (Based on MOS) $3.18
Sell Profits (Based on MOS) $8.12
Premium or (discount) MOS 1%
10 year Bond (risk free) 2.80%
Premium 5.00%
Discount Rate 7.80%
Growth (Retention Model) 39.05%
Margin of Safety 39%

manvsmonkey (77.39) Submitted: 7/28/2008 2:09:10 PM : Start Price: $7.30 ACUR Score: -29.51

seems like the phase III trial is going well

http://seekingalpha.com/article/87373-a-biotech-bloom-in-july?source=side_bar_long_ideas

rvood (< 20) Submitted: 7/23/2008 12:25:19 AM : Start Price: $7.67 ACUR Score: -29.78

New Aversion technology, phase 3 appears to be going well, licensing agreements in place, R&D being paid for by King, low float, pipeline ever increasing, starting to get looked at by funds, etc, too many druggies out there, what's not to like.

davidr825 (< 20) Submitted: 6/13/2008 7:58:39 PM : Start Price: $9.54 ACUR Score: -36.30

Unique delivery of controlled substances will make this a winner - especially when coupled with King Pharmaceutical

tcampbellla (91.38) Submitted: 10/29/2007 3:16:36 PM : Start Price: $19.30 ACUR Score: +51.20

No thanks.

odmonk (45.06) Submitted: 10/29/2007 12:54:09 AM : Start Price: $19.50 ACUR Score: +51.55

Living on borrowed money and time.